Premium
Alterations in regional brain concentrations of neurotensin and bombesin in Parkinson's disease
Author(s) -
Bissette Garth,
Nemeroff Charles B.,
Decker Michael W.,
Kizer John S.,
Agid Yves,
JavoyAgid France
Publication year - 1985
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410170403
Subject(s) - globus pallidus , substantia nigra , ventral tegmental area , neurotensin , nucleus accumbens , entorhinal cortex , putamen , medicine , endocrinology , caudate nucleus , hippocampus , neuroscience , cingulate cortex , amygdala , parkinson's disease , dopamine , neuropeptide , basal ganglia , biology , central nervous system , dopaminergic , disease , receptor
Frozen samples of postmortem human brain tissue from patients with Parkinson's disease(n = 25) and control patients who died without neurological disease (n = 25) were assayed for neurotensin and bombesin by specific radioimmunoassay. Twelve brain regions were examined: substantia nigra, ventral tegmental area, periaqueductal gray matter, caudate nucleus, putamen, globus pallidus, amygdala, hippocampus, nucleus accumbens, frontal cortex, cingulate cortex, and entorhinal cortex. In patients with Parkinson's disease, the concentration of neurotensin was significantly reduced in the hippocampus. The concentration of neither peptide was significantly altered in the substantia nigra or ventral tegmental area, two regions known to exhibit reductions in other neurotransmitter substances.